Evaluating cost-effectiveness of preventing liver cancer in patients with fatty liver disease

Comparative cost-effectiveness of HCC prevention in metabolic dysfunction associated fatty liver disease

NIH-funded research Baylor College of Medicine · NIH-10874536

This study is looking at the best ways to prevent liver cancer in people with fatty liver disease, focusing on how well different treatments, like certain medications, work and how much they cost, to help improve care for patients.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionBaylor College of Medicine NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-10874536 on NIH RePORTER

What this research studies

This research investigates the best strategies to prevent hepatocellular carcinoma (HCC) in individuals with metabolic dysfunction associated fatty liver disease (MAFLD). It aims to assess the cost-effectiveness of various prevention methods, including the use of medications like metformin and statins, while addressing the gaps in current clinical guidelines. By analyzing data and outcomes, the research seeks to provide insights into effective surveillance and prevention strategies tailored for patients with MAFLD. The ultimate goal is to reduce the burden of liver cancer and improve patient survival rates.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with metabolic dysfunction associated fatty liver disease who are at risk for developing liver cancer.

Not a fit: Patients without metabolic dysfunction associated fatty liver disease or those with advanced liver cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective prevention strategies for liver cancer, ultimately improving survival rates for patients with fatty liver disease.

How similar studies have performed: Previous research has shown promise in using similar preventive approaches for liver cancer, but this specific focus on MAFLD is relatively novel.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alcoholic Liver DiseasesCancer CauseCancer DetectionCancer Etiology
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.